Sangamo Therapeutics (SGMO)
(Delayed Data from NSDQ)
$2.81 USD
+0.34 (13.77%)
Updated Nov 7, 2024 04:00 PM ET
After-Market: $2.82 +0.01 (0.36%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$2.81 USD
+0.34 (13.77%)
Updated Nov 7, 2024 04:00 PM ET
After-Market: $2.82 +0.01 (0.36%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth F Momentum D VGM
Zacks News
Sangamo Therapeutics (SGMO) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Sangamo (SGMO) delivered earnings and revenue surprises of -13.33% and -31.19%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Bull of the Day: Illumina (ILMN)
by Madeleine Johnson
Invest in the medical space with this DNA sequencing-focused company.
Gilead (GILD) Q2 Earnings & Sales Beat Eclipsed by CEO Exit
by Zacks Equity Research
Gilead's GILD) stock is down in after-market trading as the news of departure of the company's CEO has overshadowed the company's second-quarter results, which beat estimates.
Options Traders Expect Huge Moves in Sangamo Therapeutics (SGMO) Stock
by Zacks Equity Research
Sangamo Therapeutics (SGMO) needs investors to pay close attention to the stock based on moves in the options market lately.
CRISPR Science and Stocks: Knowing Enough to Invest
by Kevin Cook
Can you learn enough about the science and the companies to invest with confidence?
Gilead Collaborates with Hookipa for HBV and HIV Therapies
by Zacks Equity Research
Gilead Sciences (GILD) collaborates with Hookipa Biotech AG for the development of immunization technologies for HBV and HIV diseases.
Gilead (GILD) Q1 Earnings & Sales Miss Estimates on Weak HCV
by Zacks Equity Research
Gilead (GILD) announced dismal results for the first-quarter as HCV sales plunged further due to increasing competition.
Has Sangamo Therapeutics (SGMO) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is Sangamo Therapeutics, Inc. (SGMO) Outperforming Other Medical Stocks This Year?
Zacks Investment Ideas feature highlights: Sangamo, bluebird, Editas, Sarepta and Juno
by Zacks Equity Research
Zacks Investment Ideas feature highlights: Sangamo, bluebird, Editas, Sarepta and Juno
Zacks Investment Ideas feature highlights: Alibaba, NVIDIA, Edwards Lifesciences, Sangamo Therapeutics and bluebird bio
by Zacks Equity Research
Zacks Investment Ideas feature highlights: Alibaba, NVIDIA, Edwards Lifesciences, Sangamo Therapeutics and bluebird bio
Sangamo Therapeutics (SGMO) Looks Good: Stock Adds 14.4% in Session
by Zacks Equity Research
Sangamo Therapeutics (SGMO) shares rose more than 14% in the last trading session, amid huge volumes.
Recession is Coming! Not
by Kevin Cook
Even if Dalio is only half right, we can bank on the "melt up" and monitor the data like an interest rate hawk
Pfizer (PFE) Collaborates With Sangamo for Gene Therapy
by Zacks Equity Research
Pfizer entered into collaboration agreements with Sangamo Therapeutics and private biotech, Arvinas.
Biotech Stock Roundup: GWPH Submits Epidiolex in the EU, Sangamo Inks Deal with Pfizer
by Arpita Dutt
Collaboration agreements announced by companies like Sangamo (SGMO) and the submission of a regulatory application for GW's Epidiolex were the key highlights this week in the biotech sector.
The Zacks Analyst Blog Highlights: ACADIA Pharmaceuticals, Sangamo Therapeutics, AnaptysBio and Sino Biopharmaceutical
by Zacks Equity Research
The Zacks Analyst Blog Highlights: ACADIA Pharmaceuticals, Sangamo Therapeutics, AnaptysBio and Sino Biopharmaceutical
4 Biotech Stocks Ready to Crush the Market in 2018
by Zacks Equity Research
The biotech sector has performed well in 2017 and we expect the momentum to continue in 2018 driven by new drug approvals. Here, we list stocks which might be worth adding to your biotech portfolio for 2018.
3 Buy-Ranked Biotech Stocks That Soared in 2017
by Benjamin Rains
The S&P 500 is up almost 20% in 2017, with the likes of technology giants Nvidia (NVDA) and Amazon (AMZN) helping lift the index to new heights.
Why Sangamo Therapeutics (SGMO) Could Be Positioned for a Surge
by Zacks Equity Research
Sangamo Therapeutics, Inc. (SGMO) is seeing solid earnings estimate revisions, and the stock is showing decent short-term momentum as well.
These 5 Stocks Have Popped More Than 100% Since Trump's Win
by Swarup Gupta
With tax cuts close to becoming law, it makes sense to pick stocks that have posted stellar performances since Trump's win.
The Zacks Analyst Blog Highlights: Sangamo Therapeutics, Sarepta Therapeutics, Akebia Therapeutics, Calithera Biosciences and GlycoMimetics
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Sangamo Therapeutics, Sarepta Therapeutics, Akebia Therapeutics, Calithera Biosciences and GlycoMimetics
5 Top-Ranked Drug Stocks that are Broker Favorites
by Arpita Dutt
With the pharma and biotech sector bouncing back in 2017, here is a look at five drug stocks including Sarepta (SRPT) that are broker favorites.
4 Biotech Stocks to Better Your Financial Health This Winter
by Zacks Equity Research
The biotech industry shows a solid performance so far this year except for a brief slump in between of late. However, it is a good idea to select stocks from a sector that is fundamentally strong.
Is GW Pharma (GWPH) Likely to Beat Earnings Estimates in Q4?
by Zacks Equity Research
GW Pharma (GWPH) will report its fiscal fourth-quarter results next week. Investors focus is expected to be on commercialization plan for Epidiolex.
Sangamo Therapeutics (SGMO) in Focus: Stock Moves 13.6% Higher
by Zacks Equity Research
Sangamo Therapeutics (SGMO) shares rose nearly 14% in the last trading session, amid huge volumes.
Best Sector ETF of Q3 and its Top-Performing Stocks
by Sweta Killa
Inside the top performing stocks of top U.S.-focused ETF of Q3.